| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Gross Sales | 9,151.18 | 8,171.16 | 7,081.55 | 6,559.1 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 9,151.18 | 8,171.16 | 7,081.55 | 6,559.1 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 207.74 | 234.88 | 279.44 | 334.83 |
Total Income | 9,358.92 | 8,406.04 | 7,360.99 | 6,893.93 |
Total Expenditure | 7,706.35 | 7,037.69 | 6,460.27 | 5,624.52 |
PBIDT | 1,652.57 | 1,368.35 | 900.72 | 1,269.41 |
Interest | 421.59 | 448.49 | 344.18 | 198.25 |
PBDT | 1,230.98 | 919.86 | 556.54 | 1,071.16 |
Depreciation | 816.34 | 740.57 | 676.69 | 586.18 |
Minority Interest Before NP | 0 | 0 | 0 | 0 |
Tax | 310.12 | 185.35 | 110.4 | 191.13 |
Deferred Tax | 13.39 | -23.88 | -44.09 | -82.11 |
Reported Profit After Tax | 91.13 | 17.82 | -186.46 | 375.96 |
Minority Interest After NP | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 91.13 | 17.82 | -186.46 | 375.96 |
Extra-ordinary Items | 0 | 2.12 | -0.56 | -9.14 |
Adjusted Profit After Extra-ordinary item | 91.13 | 15.7 | -185.9 | 385.1 |
EPS (Unit Curr.) | 0.69 | 0.14 | -1.57 | 3.19 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 |
Dividend (%) | 1.4 | 1.1 | 0 | 5.6 |
Equity | 1,324.35 | 1,322.95 | 1,193.32 | 1,185.91 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 |
PBIDTM(%) | 18.05 | 16.74 | 12.71 | 19.35 |
PBDTM(%) | 13.45 | 11.25 | 7.85 | 16.33 |
PATM(%) | 0.99 | 0.21 | -2.63 | 5.73 |
The company stated in its filing with the bourses that its remains committed to maintain highest compliance standards.
Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in these regions.
This month, the US FDA inspected the facility and after inspection issued a Form 483 of six observations as the company has to improve compliance in this regard.
In response to growing demand of IA, capacity expansions are under way at both Dahej and Digwal facilities, with month-on-month production growth.
As part of long-term strategy PCC has seen a number of product launches during recent times which are building block towards market presence in generic injectables.
The transaction falls in the internal transaction category because the parent is trading with a subsidiary.
Piramal Pharma Solutions (PPS) is set to invest $80 million in expanding its sterile injectables facility in Lexington, Kentucky, USA, projected for completion by FY27.
Piramal Pharma Limited's Chairperson, Nandini Piramal, attributed the company's development to its solid operational performance.
On September 11, 2024, and October 26, 2023, the stock reached a 52-week high of ₹244.10 and a low of ₹87.55.
Here are some of the stocks that may see significant price movement today: HCL Technologies, Lupin, Piramal Pharma, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
